Breast‐conserving therapy shows better prognosis in mucinous breast carcinoma compared with mastectomy: A SEER population‐based study
Autor: | Feng Ye, Yutian Zou, Xiaoming Xie, Peng Liu, Ping Yu, Hailin Tang, Na Li, Xinhua Xie |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty mucinous breast carcinoma medicine.medical_treatment Breast Neoplasms lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Epidemiology medicine Humans Radiology Nuclear Medicine and imaging Stage (cooking) Mucinous Breast Carcinoma skin and connective tissue diseases Pathological Mastectomy Original Research Aged Proportional hazards model business.industry Clinical Cancer Research Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Prognosis medicine.disease breast‐conserving therapy SEER Radiation therapy 030104 developmental biology 030220 oncology & carcinogenesis Female business SEER Program |
Zdroj: | Cancer Medicine Cancer Medicine, Vol 9, Iss 15, Pp 5381-5391 (2020) |
ISSN: | 2045-7634 |
Popis: | Background Mucinous breast carcinoma (MBC) is a relatively rare pathological type of breast cancer. Compared with mastectomy in MBC, the effect and safety of breast‐conserving therapy (BCT) remains unclear. Therefore, we investigated the long‐term prognosis of BCT and mastectomy in T1‐2 stage mucinous breast carcinoma via the Surveillance, Epidemiology, and End Results (SEER) database. Methods Totally, 8830 patients who were diagnosed of mucinous breast carcinoma between 2004 and 2014 from SEER database were reviewed retrospectively. Cox proportional hazards model and Kaplan‐Meier method were performed for evaluating the relationship between surgical method and prognosis. Results One thousand three hundred and twenty (14.9%) patients underwent mastectomy and 7510 (85.1%) underwent BCT. The median follow‐up time was 77 months. There were more non‐Hispanic white, married, and younger ( .05).While for patients who received BCT, the use of radiotherapy showed OS benefit. Conclusions This large population‐based study indicated patients who received BCT had better prognosis than those received mastectomy in T1‐2 stage MBC, especially in patients at the age of 50‐79 years. The use of radiotherapy showed OS benefit in patients receiving BCT. Breast‐conserving therapy might be preferred over mastectomy especially in locoregional treatment of T1‐2 stage MBC. This large population‐based study confirmed that patients with BCT had better prognosis than those with mastectomy in T1‐2 stage MBC, especially in patients with age of 50‐79 years. The use of radiotherapy show OS benefit in patients receiving BCT. Breast conserving therapy should be preferred over mastectomy in locoregional treatment of T1‐2 stage MBC. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |